Publications
2024
- Zhang L, Cheng HH, Krüger N, Hörnich B, Graichen L, Hahn AS, Schulz SR, Jäck HM, Stankov MV, Behrens GMN, Müller MA, Drosten C, Mörer O, Winkler MS, Qian Z, Pöhlmann S, Hoffmann M.
ACE2-independent sarbecovirus cell entry can be supported by TMPRSS2-related enzymes and can reduce sensitivity to antibody-mediated neutralization.
PLoS Pathog. 2024 Nov 13;20(11):e1012653. - DOI - - Hasan MZ, Claus M, Krüger N, Reusing S, Gall E, Bade-Döding C, Braun A, Watzl C, Uhrberg M, Walter L
SARS-CoV-2 infection induces adaptive NK cell responses by spike protein-mediated induction of HLA-E expression.
Emerg Microbes Infect. 2024 Dec;13(1):2361019 - DOI - - Oneto A, Hamwi GA, Schäkel L, Krüger N, Sylvester K, Petry M, Shamleh RA, Pillaiyar T, Claff T, Schiedel AC, Sträter N, Gütschow M, Müller CE
Nonpeptidic Irreversible Inhibitors of SARS-CoV-2 Main Protease with Potent Antiviral Activity.
J Med Chem. 2024 Sep 12;67(17):14986-15011 - DOI - - Stahl-Hennig C, Peter AS, Cordsmeier A, Stolte-Leeb N, Vestweber R, Socher E, Merida SA, Sauermann U, Bleyer M, Fraedrich K, Grunwald T, Winkler TH, Ensser A, Jäck H-M, Überla K
Genetic barrier to resistance: a critical parameter for efficacy of neutralizing monoclonal antibodies against SARS-CoV-2 in a nonhuman primate model.
J Virol. 2024 Jul 23;98(7):e0062824 - DOI - - Karsten CB, Buettner FFR, Cajic S, Nehlmeier I, Roshani B, Klippert A, Sauermann U, Stolte-Leeb N, Reichl U, Gerardy-Schahn R, Rapp E, Stahl-Hennig C, Pöhlmann S
Macrophage- and CD4+ T cell-derived SIV differ in glycosylation, infectivity and neutralization sensitivity.
PLoS Pathog. 2024 May 28;20(5):e1012190 - DOI - - Kaiser FK, Hernandez MG, Krüger N, Englund E, Du W, Mykytyn AZ, Raadsen MP, Lamers MM, Rodrigues Ianiski F, […], Osterhaus ADME
Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and non-human primate models.
Nat Commun. 2024 Mar 14;15(1):2319 - DOI - - Flury P, Breidenbach J, Krüger N, Voget R, Schäkel L, Si Y, Krasniqi V, Calistri S, Olfert M, Sylvester K, Rocha C, Ditzinger R, Rasch A, Pöhlmann S, Kronenberger T, Poso A, Rox K, Laufer SA, Müller CE, Gütschow M, Pillaiyar T
Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity.
ACS Pharmacol Transl Sci. 2024 Jan 19;7(2):493-514 - DOI -
2023
- Festag, J, Festag MM, Asen T, Wettengel JM, Mück-Häusl MA, Abdulhaqq S, Stahl-Hennig C, Sacha JB, Burwitz BJ, Protzer U, Wisskirchen K
Vector-Mediated Delivery of Human Major Histocompatibility Complex-I into Hepatocytes Enables Investigation of T Cell Receptor-Redirected Hepatitis B Virus-Specific T Cells in Mice, and in Macaque Cell Cultures.
Hum Gene Ther. 2023 Dec;34(23-24):1204-1218 - DOI - - Kaboudi N, Krüger N, Hamzeh-Mivehroud M
Development of novel ligands against SARS-CoV-2 Mpro enzyme: an in silico and in vitro Study.
Mol Inform. 2023 Nov;42(11):e202300120 - DOI - - Laliberté A, Prelli Bozzo C, Stahl-Hennig C, Hunszinger V, Joas S, Sauermann U, Roshani B, Klippert A, Daskalaki M, Mätz-Rensing K, [...], Kirchhoff F
Vpr attenuates antiviral immune responses and is critical for full pathogenicity of SIVmac239 in rhesus macaques.
iScience. 2023 Oct 26;26(12):108351 - DOI - - Stab V, Stahl-Hennig C, Ensser A, Richel E, Fraedrich K, Sauermann U, Tippler B, Klein F, Burton DR, Tenbusch M, Überla K
HIV-1 neutralizing antibodies provide sterilizing immunity by blocking infection of the first cells.
Cell Rep Med. 2023 Oct 17;4(10):101201 - DOI - - Budhadev D, Hooper J, Rocha C, Nehlmeier I, Kempf AM, Hoffmann M, Krüger N, Zhou D, Pöhlmann S, Guo Y
Polyvalent Nano-Lectin Potently Neutralizes SARS-CoV-2 by Targeting Glycans on the Viral Spike Protein.
JACS Au. 2023 Jun 12;3(6):1755-1766 - DOI - - Krüger N, Kronenberger T, Xie H, Rocha C, Pöhlmann S, Su H, Xu Y, Laufer SA, Pillaiyar T
Discovery of Polyphenolic Natural Products as SARS-CoV-2 Mpro Inhibitors for COVID-19.
Pharmaceuticals (Basel). 2023 Jan 28;16(2):190 - DOI -
2022
- Sidarovich A, Krüger N, Rocha C, Graichen L, Kempf A, Nehlmeier I, Lier M, Cossmann A, Stankov MV, Schulz SR, Behrens GMN, Jäck HM, Pöhlmann S, Hoffmann M
Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1.
Viruses. 2022 Nov 9;14(11):2475 - DOI - - Pillaiyar T, Flury P, Krüger N, Su H, Schäkel L, Barbosa Da Silva E, Eppler O, Kronenberger T, Nie T, Luedtke S, Rocha C, Sylvester K, Petry MRI, McKerrow JH, Poso A, Pöhlmann S, Gütschow M, O'Donoghue AJ, Xu Y, Müller CE, Laufer SA
Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure-Activity Relationships, Antiviral Activity, and X-ray Structure Determination.
J Med Chem. 2022 Jul 14;65(13):9376-9395 - DOI - - Hoffmann M, Sidarovich A, Arora P, Krüger N, Nehlmeier I, Kempf A, Graichen L, Winkler MS, Niemeyer D, Goffinet C, Drosten C, Schulz S, Jäck HM, Pöhlmann S
Evidence for an ACE2-independent entry pathway that can protect from neutralization by an antibody used for COVID-19 therapy.
mBio. 2022 Jun 28;13(3):e0036422 - DOI - - Runft S, Färber I, Krüger J, Krüger N, Armando F, Rocha C, Pöhlmann S, Burigk L, Leitzen E, Ciurkiewicz M, Braun A, Schneider D, Baumgärtner L, Freisleben B, Baumgärtner W
Alternatives to animal models and their application in the discovery of species susceptibility to SARS-CoV-2 and other respiratory infectious pathogens: A review.
Vet Pathol. 2022 Jul;59(4):565-577 - DOI - - Arora P, Zhang L, Krüger N, Rocha C, Sidarovich A, Schulz S, Kempf A, Graichen L, Moldenhauer AS, Cossmann A, Dopfer-Jablonka A, Behrens GMN, Jäck HM, Pöhlmann S, Hoffmann M
SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies.
Cell Host Microbe. 2022 Aug 10;30(8):1103-1111.e6 - DOI - - Färber I, Krüger J, Rocha C, Armando F, von Köckritz-Blickwede M, Pöhlmann S, Braun A, Baumgärtner W, Runft S, Krüger N
Investigations on SARS-CoV-2 Susceptibility of Domestic and Wild Animals Using Primary Cell Culture Models Derived from the Upper and Lower Respiratory Tract.
Viruses. 2022 Apr 16;14(4):828 - DOI -
2021
- Hoffmann M, Krüger N, Schulz S, Cossmann A, Rocha C, Kempf A, Nehlmeier I, Graichen L, Moldenhauer AS, Winkler MS, Lier M, Dopfer-Jablonka A, Jäck HM, Behrens GMN, Pöhlmann S
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.
Cell. 2022 Feb 3;185(3):447-456.e11 - DOI - - Hempel T, Elez K, Krüger N, Raich L, Shrimp JH, Danov O, Jonigk D, Braun A, Shen M, Hall MD, Pöhlmann S, Hoffmann M, Noé F
Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties.
Chem Sci. 2021 Aug 26;12(38):12600-12609 - DOI - - Arora P, Sidarovich A, Krüger N, Kempf A, Nehlmeier I, Graichen L, Moldenhauer AS, Winkler MS, Schulz S, Jäck HM, Stankov MV, Behrens GMN, Pöhlmann S, Hoffmann M
B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination.
Cell Rep. 2021 Oct 12;37(2):109825 - DOI - - Krüger N, Rocha C, Runft S, Krüger J, Färber I, Armando F, Leitzen E, Brogden G, Gerold G, Pöhlmann S, Hoffmann M, Baumgärtner W
The Upper Respiratory Tract of Felids Is Highly Susceptible to SARS-CoV-2 Infection.
Int J Mol Sci. 2021 Sep 30;22(19):10636 - DOI - - Hoffmann M, Hofmann-Winkler H, Krüger N, Kempf A, Nehlmeier I, Graichen L, Arora P, Sidarovich A, Moldenhauer AS, Winkler MS, Schulz S, Jäck HM, Stankov MV, Behrens GMN, Pöhlmann S
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination.
Cell Rep. 2021 Jul 20;36(3):109415 - DOI - - Ritzmann F, Chitirala P, Krüger N, Hoffmann M, Zuo W, Lammert F, Smola S, Tov N, Alagem N, Lepper PM, Pöhlmann S, Beisswenger C, Herr C, Bals R
Therapeutic Application of alpha-1-antitrypsin in COVID-19.
Am J Respir Crit Care Med. 2021 Jul 15;204(2):224-227 - DOI - - Hoffmann M, Zhang L, Krüger N, Graichen L, Kleine-Weber H, Hofmann-Winkler H, Kempf A, Nessler S, Riggert J, Winkler MS, Schulz S, Jäck HM, Pöhlmann S
SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization.
Cell Rep. 2021 Apr 20;35(3):109017 - DOI - - Hoffmann M, Arora P, Groß R, Seidel A, Hörnich BF, Hahn AS, Krüger N, Graichen L, Hofmann-Winkler H, Kempf A, Winkler MS, Schulz S, Jäck HM, Jahrsdörfer B, Schrezenmeier H, Müller M, Kleger A, Münch J, Pöhlmann S
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
Cell. 2021 Apr 29;184(9):2384-2393.e12 - DOI - - Hoffmann M, Hofmann-Winkler H, Smith JC, Krüger N, Arora P, Sørensen LK, Søgaard OS, Hasselstrøm JB, Winkler M, Hempel T, Raich L, Olsson S, Danov O, Jonigk D, Yamazoe T, Yamatsuta K, Mizuno H, Ludwig S, Noé F, Kjolby M, Braun A, Sheltzer JM, Pöhlmann S
Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
EBioMedicine. 2021 Mar;65:103255 - DOI -
2020
- Hüttl S, Hoffmann M, Steinmetzer T, Sauder C, Krüger N
The amino acid at position 8 of the proteolytic cleavage site of the mumps virus fusion protein affects viral proteolysis and fusogenicity.
J Virol. 2020 Oct 27;94(22):e01732-20 - DOI - - Hoffmann M, Mösbauer K, Hofmann-Winkler H, Kaul A, Kleine-Weber H, Krüger N, Gassen NC, Müller MA, Drosten C, Pöhlmann S
Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2.
Nature. 2020 Sep;585(7826):588-590 - DOI - - Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Cell. 2020 Apr 16;181(2):271-280.e8 - DOI - - Kleine-Weber H, Schroeder S, Krüger N, Prokscha A, Naim HY, Müller MA, Drosten C, Pöhlmann S, Hoffmann M
Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus.
Emerg Microbes Infect. 2020 Jan 21;9(1):155-168 - DOI -